Alternative Links zum Volltext:DOIVerlag
| Dokumentenart: | Artikel |
|---|
| Titel eines Journals oder einer Zeitschrift: | DMW - Deutsche Medizinische Wochenschrift |
|---|
| Verlag: | GEORG THIEME VERLAG KG |
|---|
| Ort der Veröffentlichung: | STUTTGART |
|---|
| Band: | 146 |
|---|
| Nummer des Zeitschriftenheftes oder des Kapitels: | 19 |
|---|
| Seitenbereich: | S. 1283-1286 |
|---|
| Datum: | 2021 |
|---|
| Institutionen: | Medizin > Zentren des Universitätsklinikums Regensburg > Tumorzentrum e.V. |
|---|
| Identifikationsnummer: | | Wert | Typ |
|---|
| 10.1055/a-1393-7697 | DOI |
|
|---|
| Stichwörter / Keywords: | POSITIVE SOLID TUMORS; CHEMOTHERAPY; immunotherapy; targeted therapy; National Network Genomic Medicine Lung Cancer |
|---|
| Dewey-Dezimal-Klassifikation: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin |
|---|
| Status: | Veröffentlicht |
|---|
| Begutachtet: | Ja, diese Version wurde begutachtet |
|---|
| An der Universität Regensburg entstanden: | Ja |
|---|
| Dokumenten-ID: | 55834 |
|---|
Web of Science
Zusammenfassung
Immuno-oncologic monotherapy for NSCLC 5-year survival data from the KEYNOTE-024 trial confirm the sustained efficacy of immuno-oncologic monotherapy in patients with NSCLC with high PD-L1 expression (>= 50%). Dual immunotherapy in combination with chemotherapy as first-line therapy for NSCLC Nivolumab plus impilimumab in combination with 2 cycles of platinum-containing chemotherapy improves ...
Zusammenfassung
Immuno-oncologic monotherapy for NSCLC 5-year survival data from the KEYNOTE-024 trial confirm the sustained efficacy of immuno-oncologic monotherapy in patients with NSCLC with high PD-L1 expression (>= 50%). Dual immunotherapy in combination with chemotherapy as first-line therapy for NSCLC Nivolumab plus impilimumab in combination with 2 cycles of platinum-containing chemotherapy improves survival in NSCLC patients. Novel targets and treatment options Entrectinib and larotrectinib with efficacy in NTRK fusion-positive NSCLC. Selpercatinib and pralsetinib with efficacy in RET fusion-positive NSCLC. Mobocertinib with efficacy in EGFRex20ins mutation of the EGFR gene. Sotorasib with efficacy in kRAS-G12C mutation of NSCLC. National Network Genomic Medicine Lung Cancer (nNGM) The nationwide network nNGM provides NSCLC patients with access to state-of-the-art molecular diagnostics and the latest treatment options.
Altmetric